Patents by Inventor Jianming Yu
Jianming Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250118700Abstract: A semiconductor device includes: a first wire bonding area with a first bonding pad, a second wire bonding area with a second bonding pad, and a first bonding wire connecting the first bonding pad to the second bonding pad. The first bonding wire includes a lower pressing section and a first line segment connecting the lower bonding part to the first bonding pad. A distance between the lower pressing section and a plane where the second wire bonding area is located is defined as a first height, which is smaller than 400 ?m, a length of an orthographic projection of the first bonding wire on the plane is defined as a first length, a length of an orthographic projection of the first line segment on the plane is defined as a second length, and the second length is 20%-80% of the first length.Type: ApplicationFiled: September 30, 2024Publication date: April 10, 2025Inventors: Xiaopeng GUO, Jianming YU, Ziyuan WANG, Junrui LUO, Lijiao LIU
-
Patent number: 12268694Abstract: The present invention relates to a pharmaceutical composition useful for treating a Respiratory Syncytial Virus (RSV) infection, comprising a compound which is or a pharmaceutically acceptable salt thereof, and a second anti-respiratory syncytial virus agent.Type: GrantFiled: November 10, 2020Date of Patent: April 8, 2025Assignee: Enanta Pharmaceuticals, Inc.Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph Panarese, Kai Lin, Michael H. J. Rhodin, Nicole V. McAllister, Yat Sun Or
-
Patent number: 12227736Abstract: The present invention discloses Stenotrophomonas maltophilia GYH and its application in degrading chlorinated hydrocarbon pollutants, and the application is carried out as follows: resting cells obtained by spreading cultivation of Stenotrophomonas maltophilia GYH are added to a pH=5-8 inorganic salt medium, and then a chlorinated hydrocarbon pollutant is added, and the cells are cultured at 20-35° C. and 140-180 rpm to degrade the pollutant. The concentration of chlorinated hydrocarbon pollutant which can be removed by Stenotrophomonas maltophilia GYH ranges from 2.9 mg/L to 8.93 mg/L. Therefore, the Stenotrophomonas maltophilia has a highly efficient degradation ability for similar industrial pollutants and is able to withstand high concentrations of these pollutants.Type: GrantFiled: July 31, 2020Date of Patent: February 18, 2025Assignee: ZHEJIANG UNIVERSITY OF TECHNOLOGYInventors: Zhuowei Cheng, Dongzhi Chen, Jiade Wang, Jianming Yu, Jianmeng Chen, Yanhong Guan
-
Patent number: 12162857Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the compounds of Formula (I) for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: April 26, 2023Date of Patent: December 10, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Jianming Yu, Xiben Li, Robert Leon, Adam Szymaniak, In Jong Kim, Yat Sun Or
-
Publication number: 20240368174Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: April 5, 2024Publication date: November 7, 2024Inventors: Adam SZYMANIAK, Robert LEON, Kevin McGRATH, Xiben LI, Tyler J. MANN, Jianming YU, In Jong KIM, Scott MITCHELL, Yat Sun OR
-
Publication number: 20240368176Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: April 26, 2024Publication date: November 7, 2024Inventors: Adam SZYMANIAK, Kevin McGRATH, Jianming YU, Tyler J. MANN, Long NGUYEN, Kaicheng ZHU, In Jong KIM, Yat Sun OR
-
Publication number: 20240360155Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: February 22, 2024Publication date: October 31, 2024Inventors: Brian C. SHOOK, In Jong KIM, Thomas P. BLAISDELL, Jianming YU, Joseph D. PANARESE, Yat Sun OR
-
Publication number: 20240360117Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: January 24, 2024Publication date: October 31, 2024Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or
-
Publication number: 20240327334Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 20, 2023Publication date: October 3, 2024Inventors: Xuri GAO, Bin WANG, Hui CAO, Jiajun ZHANG, Yuk Ming SIU, Jiang LONG, Wei LI, Matthew C. RHODES, Xuechao XING, Jianming YU, Scott MITCHELL, Yat Sun OR
-
Patent number: 12093200Abstract: Methods for USB signal communication over an optical link are described. One aspect includes detecting connection of a device circuit to a USB device. The detecting may further include transmitting an electrical pulse through a reactive network, and detecting a change in a delay associated with the electrical pulse responsive to connecting the device circuit to the USB device. An optical signal associated with the detected connection may be transmitted to a host circuit via an optical communication channel.Type: GrantFiled: August 4, 2021Date of Patent: September 17, 2024Assignee: WINGCOMM CO. LTD.Inventors: Jianming Yu, Zuodong Wang, Wei Mao, Yun Bai
-
Patent number: 12034483Abstract: Systems and methods for optical transmission of one-or-more out-of-band signals associated with audio-video signal communication are described. In one aspect, an optical receiver receives a first out-of-band electrical signal and a second out-of-band electrical signal from a video sink. The first out-of-band electrical signal may correspond to an audio-video stream previously received or concurrently being received from a video source optical transmitter at the optical receiver. The second out-of-band electrical signal may also correspond to the audio-video stream. The optical receiver may combine the first out-of-band electrical signal and the second out-of-band electrical signal into a transmit electrical signal. In one aspect, the optical receiver converts the transmit electrical signal into an optical signal, and transmits the optical signal to an optical transmitter via an optical communication channel.Type: GrantFiled: June 7, 2022Date of Patent: July 9, 2024Assignee: WINGCOMM CO. LTD.Inventors: Jianming Yu, Zuodong Wang, Wei Mao, Yun Bai
-
Patent number: 12006326Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: August 24, 2022Date of Patent: June 11, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Adam Szymaniak, Kevin McGrath, Jianming Yu, Tyler Mann, Long Nguyen, Kaicheng Zhu, In Jong Kim, Yat Sun Or
-
Patent number: 11970902Abstract: A rotary positioning adjustment device includes a shaft sleeve and a connecting rod. A reel is fixedly connected with an end of the connecting rod; a fixed seat is sleeved on the connecting rod; the reel is arranged in the fixed seat; and a power storage assembly is installed in the shaft sleeve. The power storage assembly includes a power input piece, a second torsion spring and a power output piece; a first support leg of the second torsion spring is connected in a hooked mode with one side of an input block of the power input piece, and a second support leg of the second torsion spring is connected in a hooked mode with the other side of the input block. A curtain includes the rotary positioning adjustment device.Type: GrantFiled: September 14, 2020Date of Patent: April 30, 2024Assignee: LANTEX WINDOW FASHIONS CO., LTDInventors: Jianming Yu, Binglu Qiu, Chaozhong Wang
-
Patent number: 11952389Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: May 3, 2022Date of Patent: April 9, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Brian C. Shook, In Jong Kim, Thomas P. Blaisdell, Jianming Yu, Joseph D. Panarese, Yat Sun Or
-
Patent number: 11945830Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Human Respiratory Syncytial Virus (HRSV) or Human Metapneumovirus (HMPV) inhibitors. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HRSV or HMPV infection. The invention also relates to methods of treating an HRSV or HMPV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: February 24, 2022Date of Patent: April 2, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Adam Szymaniak, Jianming Yu, Kevin McGrath, Xiben Li, Tyler J. Mann, Robert Leon, In Jong Kim, Yat Sun Or, Long Nguyen
-
Patent number: 11912695Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: January 13, 2022Date of Patent: February 27, 2024Assignee: Enanta Pharmaceuticals, Inc.Inventors: Kaicheng Zhu, Kevin McGrath, Solymar Negretti-Emmanuelli, Adam Szymaniak, Jianming Yu, In Jong Kim, Yat Sun Or
-
Patent number: 11888523Abstract: Systems and methods to implement a USB and Thunderbolt optical signal transceiver are described. One method includes detecting presence of a USB sideband signal received over an optical communication channel and associated with a USB communication request. Responsive to the detecting, the method may determine that the USB communication request corresponds to a USB communication mode and perform a sideband negotiation. The USB communication mode may be enabled. A specified number of channels associated with the USB communication request may be determined. USB communication may be performed using the specified number of channels over the optical communication channel in the USB communication mode.Type: GrantFiled: December 9, 2021Date of Patent: January 30, 2024Assignee: WINGCOMM CO. LTD.Inventors: Jianming Yu, Zuodong Wang, Wei Mao, Yun Bai
-
Patent number: 11876562Abstract: Systems and methods to implement a USB and Thunderbolt optical signal transceiver are described. One method includes detecting presence of a USB sideband signal received over an optical communication channel and associated with a USB communication request. Responsive to the detecting, the method may determine that the USB communication request corresponds to a USB communication mode and perform a sideband negotiation. The USB communication mode may be enabled. A specified number of channels associated with the USB communication request may be determined. USB communication may be performed using the specified number of channels over the optical communication channel in the USB communication mode.Type: GrantFiled: December 9, 2021Date of Patent: January 16, 2024Assignee: WINGCOMM CO. LTD.Inventors: Jianming Yu, Zuodong Wang, Wei Mao, Yun Bai
-
Publication number: 20230421342Abstract: Systems and methods for HDMI signal communication over an optical communication link are described. One aspect includes receiving an HDMI control signal from an HDMI master device, and another HDMI control signal from an HDMI sink terminal via a communication resources. The method identifies half-duplex communication resource contention between the HDMI control signal and the other HDMI control signal, and transitions a communication direction of the half-duplex communication resources to give the HDMI control signal precedence over the other HDMI control signal. Subsequent to transitioning the communication direction, the method transfers the HDMI control signal to the HDMI sink terminal via the communication resources. Subsequent to transferring the HDMI control signal, the method again transitions the direction of the half-duplex communication resources, and transfers the other HDMI control signal to the HDMI master device.Type: ApplicationFiled: September 8, 2023Publication date: December 28, 2023Inventors: Jianming Yu, Zuodong Wang, Wei Mao, Yun Bai
-
Patent number: 11855693Abstract: Systems and methods to transmit audio-video signals over an optical communication channel are described. One aspect includes receiving a plurality of audio-video electrical signals at an optical transmitter. The optical transmitter may also receive a plurality of out-of-band electrical signals. The optical transmitter may collectively modulate the audio-video electrical signals to generate a composite electrical signal. In one aspect, the optical transmitter bias current-modulates a bias current level of the composite electrical signal using the electrical out-of-band signals, and generates a modulated electrical signal based on the bias current-modulating. The optical transmitter may convert the modulated electrical signal into a modulated optical signal using a laser diode, and transmit the modulated optical signal to an optical receiver over an optical communication channel.Type: GrantFiled: June 7, 2022Date of Patent: December 26, 2023Assignee: WINGCOMM Co. Ltd.Inventors: Jianming Yu, Zuodong Wang, Wei Mao, Yun Bai